# **Uppsala Longitudinal Study of Adult Men**

https://neurodegenerationresearch.eu/survey/uppsala-longitudinal-study-of-adult-men/

#### Title of the cohort

Uppsala Longitudinal Study of Adult Men

## Acronym for cohort

**ULSAM** 

## Name of Principal Investigator

Title Professor

First name Lars

Last name Lannfelt

#### Address of institution where award is held

Institution Dept of Public Health and Caring Sciences/Geriatrics

Street Address

City Uppsala Postcode 75185

### Country

Sweden

#### Website

www.pubcare.uu.se/ULSAM

#### Contact email

vilmantas.giedraitis@pubcare.uu.se

#### **Funding source**

- 1. The cohort includes, or expects to include, incidence of the following conditions
  - Alzheimer's disease and other dementias
  - Neurodegenerative disease in general

## When studies on the above condition(s) are expected to become possible

Already possible

#### 2a. Stated aim of the cohort

Increased knowledge about the following disorders in an ageing population: cardiovascular and dementia disorders, diabetes, osteoporosis, nutrition and muscle function, and successful ageing

#### 2b. Features distinguishing this cohort from other population cohorts

## 3a. i) Number of publications that involve use of cohort to date

100

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

3b. Publication list/link to where data or publications are accessible (if available)

3c. Information (i.e. research findings) expected to be gained from the population cohort

4a. Study criteria: age range of participants at recruitment

Age in years from: 50 years

To ('until death' if applicable): 90+/until death

4b. Study criteria: inclusion criteria

50-year old men living in Uppsala in 1970-1974

4c. Study criteria: exclusion criteria

None

- 5. Size of the cohort (i.e. number of participants enrolled)
  - 1,000 5,000 participants

## 6a. Measures used to characterise participants

Vascular risk factors, specified dementia disorders, nutrition and muscle metabolism, detailed data on glucose and insulin metabolism, osteoporosis measurements, successful ageing

6b. Additional measures for participants with a clinical disorder

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

AD and other dementia disorders, death, stroke etc, successful ageing

- 7. Study design
  - Prospective cohort
- 8. Cases matched by

Age

- 9a. Does the study include a specialised subset of control participants
  - No

9b. If yes, description of specialised subset of control participants 10a. i) Data collection start date

## 10a. ii) Data collection end date 10a iii) Data collection for this study is

Data analysis ongoing

## 10b. Plans to continue the cohort study beyond the current projected end date

No.

#### 11. Data collected

- Only through the study
- Through links to medical records
- Through links to other records or registers (such as dental records, police records etc). Please specify
  - Death register, National Inpatient Register

## 12. System in place to enable re-contact with patients for future studies

 Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

### 13a. Format and availability of data stored in a database

Language used:

13b. Format and availability of data held as individual records

Language used:

14a. Are data available to other groups

Yes

# 14b. Access policy/mechanisms for access if data are available to other groups

15. Data sharing policy specified as a condition of use

No requirement to make data publicly available

# 16a. Are tissues/samples/DNA available to other groups

Yes

## 16b. i) Description of available tissues/samples/DNA

Living donors: DNA

#### 16b. ii) Form available tissues/samples/DNA are supplied in

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

# 17. Is information on biological characteristics available to other groups